



For immediate release

28 April 2006

**ANGEL BIOTECHNOLOGY HOLDINGS PLC**  
**(“Angel” or “the Company”)**

**Angel strengthens business development team**

**Angel Biotechnology Holdings plc**, (AIM: ABH) the biopharmaceutical contract manufacturer, is pleased to announce the appointment of two new Business Development Managers, Ian Hallet and Gary Oliff.

Ian will be responsible for continuing to build Angel’s North American customer base. He brings with him more than 20 years experience in research and business development within the pharmaceutical and contract research industries, most recently with Cambrex Biosciences. Prior to that, he worked at Quintiles where he was responsible for business development of the preclinical pharmacology and toxicology services worldwide and established Quintiles’ safety pharmacology services as a global leader with business from Europe, America, Japan, Korea and Australia. Ian has an MPhil in Cardiovascular Pharmacology from the University of Wales College of Medicine and a BSc in Biology from the University of Stirling.

Gary will be responsible for leading business development activities in Europe. Gary has more than 20 years’ extensive experience in the medical, diagnostic, pharmaceutical, contract research and manufacturing industries. Most recently, he was European Account Manager for Biotechnology Services at Covance Laboratories Ltd and prior to that gained industry expertise at Excell Biotech Ltd and Q-One Biotech Ltd. Gary has a Degree in Biomedical Sciences from Glasgow Caledonian University.

**Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said:** “Due the increased demand for Angel’s services, we are delighted to have appointed Gary and Ian to Angel’s global Business Development Team and I take this opportunity of welcoming them to the business. The extensive expertise and industry contacts which these highly experienced individuals bring to Angel are tremendous assets that will greatly assist Angel in expansion of its business.”

**For further information, please call:**

**Angel Biotechnology Holdings plc**  
Gordon Sherriff – COO

Tel 01670 591920  
Tel 07951 057016

**Buchanan Communications**  
Lisa Baderoon/Mary-Jane Johnson

Tel 020 7466 5000

**About Angel Biotechnology Holdings plc**

Angel Biotechnology Holdings plc is a fast growing biomanufacturing company offering process development services and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo, SmithKline Beecham and Serologicals Inc.

Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at Pentlands Science Park, near Edinburgh.

Angel was established in 2000 and was admitted to trading on AIM in November 2005.